References

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2024 · External reference

Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

10.1016/s0140-6736(17)33326-3 · 2018 · External reference

New promises and challenges in the treatment of advanced non-small-cell lung cancer

10.1016/s0140-6736(24)01029-8 · 2024 · External reference

Biologics for novel driver altered non-small cell lung cancer: potential and pitfalls

10.1016/j.critrevonc.2025.104748 · 2025 · External reference

Mechanism of Drug Tolerant Persister Cancer Cells: The Landscape and Clinical Implication for Therapy

10.1016/j.jtho.2021.07.017 · 2021 · External reference

Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer

10.1101/cshperspect.a037895 · 2022 · External reference

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study

10.1200/jco.22.01989 · 2023 · External reference

Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed individual patient data meta-analysis

10.1016/s1470-2045(25)00429-2 · 2025 · External reference

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC

10.1016/j.jtho.2018.03.035 · 2018 · External reference

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

10.1093/annonc/mdz167 · 2019 · External reference

Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy

10.1038/s41571-023-00789-4 · 2023 · External reference

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

10.1038/s41588-018-0312-8 · 2019 · External reference

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

10.1001/jamaoncol.2022.1981 · 2022 · External reference

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

10.1136/jitc-2021-002891 · 2021 · External reference

Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer

10.1111/cas.13860 · 2019 · External reference

Downregulation of PD-L1 and HLA-I in non-small cell lung cancer with ALK fusion

10.1111/1759-7714.14372 · 2022 · External reference

The cancer-immunity cycle: Indication, genotype, and immunotype

10.1016/j.immuni.2023.09.011 · 2023 · External reference

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

10.1016/j.cell.2010.02.027 · 2010 · External reference

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

10.1038/s41698-022-00337-w · 2022 · External reference

The blockade of immune checkpoints in cancer immunotherapy

10.1038/nrc3239 · 2012 · External reference

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

10.1186/s13046-022-02264-x · 2022 · External reference

Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies

10.1186/s40164-024-00481-y · 2024 · External reference

Transcriptome-level discovery of survival-associated biomarkers and therapy targets in non-small-cell lung cancer

10.1111/bph.16257 · 2024 · External reference

Lung cancer in never-smokers

10.1183/09031936.00046915 · 2015 · External reference

Genome-wide CRISPR screen identifies IRF1 and TFAP4 as transcriptional regulators of Galectin-9 in T cell acute lymphoblastic leukemia

10.1126/sciadv.ads8351 · 2025 · External reference

Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells

10.1016/j.immuni.2014.06.011 · 2014 · External reference

Anti-apoptotic effect by the suppression of IRF1 as a downstream of Wnt/beta-catenin signaling in colorectal cancer cells

10.1038/s41388-019-0856-9 · 2019 · External reference

Discovery of toxoflavin, a potent IRE1alpha inhibitor acting through structure-dependent oxidative inhibition

10.1038/s41401-022-00949-9 · 2023 · External reference

Emerging roles for the ER stress sensor IRE1alpha in metabolic regulation and disease

10.1074/jbc.rev119.007036 · 2019 · External reference

RSV replication modifies the XBP1s binding complex on the IRF1 upstream enhancer to potentiate the mucosal anti-viral response

10.3389/fimmu.2023.1197356 · 2023 · External reference

ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors

10.1158/0008-5472.can-17-1904 · 2018 · External reference

Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target

10.3389/fcell.2023.1332205 · 2023 · External reference

T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins

10.1136/jitc-2022-005714 · 2023 · External reference

Structural analysis of the human galectin-9 N-terminal carbohydrate recognition domain reveals unexpected properties that differ from the mouse orthologue

10.1016/j.jmb.2007.09.060 · 2008 · External reference

The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)

2024 · External reference

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations

10.1200/jco.21.01626 · 2022 · External reference

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

10.1016/j.annonc.2023.10.117 · 2024 · External reference

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

10.1016/s1470-2045(18)30649-1 · 2018 · External reference

Immunotherapy in non-small cell lung cancer harbouring driver mutations

10.1016/j.ctrv.2021.102179 · 2021 · External reference

The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells

10.1158/1078-0432.ccr-25-1693 · 2025 · External reference

Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells

10.1002/cncr.23239 · 2008 · External reference

Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma

10.1158/0008-5472.can-10-4179 · 2011 · External reference

Galectin-9-An Emerging Glyco-Immune Checkpoint Target for Cancer Therapy

10.3390/ijms26167998 · 2025 · External reference

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

10.1182/blood-2011-06-360321 · 2012 · External reference

Differential impact of TIM-3 ligands on NK cell function

2025 · External reference

The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy

10.1016/j.canlet.2021.04.011 · 2021 · External reference

Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells

10.1158/2326-6066.cir-15-0266 · 2016 · External reference

Secretion of Galectin-9 as a DAMP during Dengue Virus Infection in THP-1 Cells

10.3390/ijms18081644 · 2017 · External reference

Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer

10.1016/j.lungcan.2021.03.018 · 2021 · External reference

Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer

10.21037/tlcr-21-92 · 2021 · External reference

The Dual Role of the NFATc2/galectin-9 Axis in Modulating Tumor-Initiating Cell Phenotypes and Immune Suppression in Lung Adenocarcinoma

10.1002/advs.202306059 · 2024 · External reference

Opposing tumor-cell-intrinsic and -extrinsic roles of the IRF1 transcription factor in antitumor immunity

10.1016/j.celrep.2024.114289 · 2024 · External reference

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

10.1158/1078-0432.ccr-18-4142 · 2019 · External reference

Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma

10.1016/j.intimp.2015.09.017 · 2015 · External reference

LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation

10.1016/j.immuni.2024.01.010 · 2024 · External reference

Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B

10.1158/1078-0432.ccr-25-0806 · 2025 · External reference

NK Cell Exhaustion

10.3389/fimmu.2017.00760 · 2017 · External reference

Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties

10.1371/journal.pone.0014062 · 2010 · External reference

A phase I dose escalation and expansion trial of lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) alone and in combination with venetoclax/HMA in Relapsed/Refractory AML/MDS

10.1182/blood-2025-1648 · 2025 · External reference

Interrogating glioma-M2 macrophage interactions identifies Gal-9/Tim-3 as a viable target against PTEN-null glioblastoma

10.1126/sciadv.abl5165 · 2022 · External reference

Priming of Human Resting NK Cells by Autologous M1 Macrophages via the Engagement of IL-1beta, IFN-beta, and IL-15 Pathways

10.4049/jimmunol.1500325 · 2015 · External reference

Anti-galectin-9 therapy synergizes with EGFR inhibition to reprogram the tumor microenvironment and overcome immune evasion

10.1136/jitc-2024-010926 · 2025 · External reference

Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia

1996 · External reference

Systematic Functional Annotation of Somatic Mutations in Cancer

10.1016/j.ccell.2018.01.021 · 2018 · External reference